RTP Mobile Logo

Saturday, April 14, 2018, Chicago, IL, 7:00 PM - 9:00 PM

Interactive Tumor Panel: Clinical Investigators Discuss Available Research Shaping the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

Event Details

Hyatt Regency Chicago
151 East Wacker Drive
Chicago, IL 60601
Hotel Phone: (312) 565-1234

Event Time (Central Time):
6:30 PM – 7:00 PM — Registration and Buffet Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room:
Columbus Hall G-L — East Tower, Ballroom/Gold Level

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Hossein Borghaei, DO, MS
Chief, Thoracic Medical Oncology
Co-Leader, Thoracic Cancer Service Line
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Leena Gandhi, MD, PhD
Director, Perlmutter Cancer Center
Langone Health
New York University
New York, New York

Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Roy S Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Neil Love, MD
Research To Practice
Miami, Florida

This symposium is accredited by Research To Practice and supported by a grant from AstraZeneca Pharmaceuticals LP. This is not an official program of the American Association for Cancer Research Annual Meeting.


This 2-hour CME symposium will feature 5 investigators with expertise in the management of lung cancer reviewing available clinical research data, ongoing investigational efforts and the practical integration of immune checkpoint inhibitors into the care of patients with this disease. Research To Practice (RTP) president and medical oncologist Dr Neil Love will moderate the program. Leading up to the event, the faculty members will provide RTP with a number of instructional, deidentified cases from their practices of patients with lung cancer evaluated for or treated with an immune checkpoint inhibitor on or off study. Radiographic or pathologic imagery will be included as part of these discussions as applicable. The program agenda will be divided into 5 topic modules, each beginning with the review of 1 or more of the faculty cases. After panel discussion, one of the faculty members will deliver a short presentation highlighting the emerging clinical and translational research relevant to the cases in question.

To foster a more interactive environment, clinicians in attendance will use networked iPads® to complete a premeeting survey related to the cases and topics selected for presentation. Survey results will be interspersed throughout each module to generate additional debate among the faculty panelists. Furthermore, to provide attendees a means of asking questions, receiving feedback and interacting with their peers, RTP will also recruit an additional lung cancer investigator to serve as an Audience Engagement Liaison. This faculty member will be responsible for interacting with, posing questions to and encouraging dialogue among attendees via a virtual chat room facilitated on the networked iPads. At select points during the meeting, Audience Engagement Liaison will share thought-provoking queries and comments made in the chat room with the moderator and panelists on stage to introduce this information to the entire audience.

Full agenda to be announced by mid-March.

CE Information

Target Audience:
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists, oncology nurses and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Analyze the biologic basis for the development of immune checkpoint inhibitors designed to boost an individual’s immune response to combat cancer.
  • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure PD-L1 status, assess which testing platforms should be used and appropriately employ the results to individualize first and later-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) based on their potential response (or lack thereof) to an immune checkpoint inhibitor.
  • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational anti-PD-1/PD-L1 antibodies for the treatment of NSCLC to determine the current and/or potential utility of these agents in clinical practice.
  • Review published research documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
  • Appraise emerging research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable Stage III NSCLC whose disease has not progressed after standard platinum-based chemotherapy concurrent with radiation therapy.
  • Describe the biologic rationale for and current clinical role of anti-PD-1/PD-L1 antibodies alone or in combination with other therapeutic approaches for small cell lung cancer (SCLC).
  • Describe ongoing research to assist in the identification of additional biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with lung cancer.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic and systemic therapies for NSCLC and SCLC, and counsel appropriate patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of this activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.


Hyatt Regency Chicago
151 East Wacker Drive
Chicago, IL 60601
Hotel Phone: (312) 565-1234

Meeting Room:
Columbus Hall G-L — East Tower, Ballroom/Gold Level


This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists, oncology nurses and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.